Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure

European Journal of Heart Failure

Volumn 15, Issue 1, 2013, Pages 79-84

  Komajda, Michel ^a   Böhm, Michael ^b   Borer, Jeffrey ^c   Ford, Ian ^d   Krum, Henry ^e   Tase, Adrian ^f   Tavazzi, Luigi ^g   Swedberg, Karl ^h  

^a SORBONNE UNIVERSITÉ   (France)

^b SAARLAND UNIVERSITY   (Germany)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF PITESTI   (Romania)

^g Research Ettore Sansavini Health Science Foundation   (Italy)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Heart failure; Heart rate; Ivabradine; Mineralocorticoid receptor antagonist

Indexed keywords

CANRENOATE POTASSIUM; CANRENOIC ACID; CANRENONE; EPLERENONE; IVABRADINE; PLACEBO; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUS RHYTHM; SYSTOLIC HEART FAILURE;

BENZAZEPINES; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84871182616     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs127     Document Type: Article

References (12)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
3. Pitt B, RemmeW, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-1321.
4. Zannad F, McMurray JJ, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
5. Armstrong PW. Aldosterone antagonists-last man standing? N Engl J Med 2011; 364:79-80.
6. Swedberg K, Komajda M, Böhm M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet 2010;376:875-885.
7. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA. Effects of highdose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840-1848.
8. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010;12:1076-1084.
9. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure : the Systolic Heart Failure Treatment with the I(f)Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010;12:75-81.
10. Dickstein K, Cohen-Solal A, Filippatos G, Mac Murray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, Van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, Mac Gregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Tendera M, Auricchio A, Bax J, Boehm M, Corra U, la Bella P, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt Freek WA, Zamorano JL, Zannad F. ESC Guidelines for the diagnosis treatment of acute chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
11. Deedwania P, Carbajal E, Dietz R, Mukherjee R, Van Mieghem W, Zannad F. Heart rate is a powerful predictor of mortality in post-AMI patients with heart failure: results from the EPHESUS trial. Abstract 3632. Eur Heart J 2006; 27(suppl 1):590.
12. Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Heart rate as a risk factor in chronic heart failure (SHIFT) : the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886-894.